Epoprostenol Injection (Flolan®, Veletri®, generic)

Covered: Epoprostenol (Flolan®, Veletri®, generic) is covered for FDA‑approved pulmonary arterial hypertension (WHO Group I) and compendial off‑label use for chronic thromboembolic pulmonary hypertension (CTEPH); other indications are not covered. Key requirements: PAH requires right‑heart catheterization confirmation, documented WHO functional class and specified prior therapy/vasodilator testing details for idiopathic PAH, prescribing or consultation by a pulmonologist/cardiologist, continuous IV administration with specified titration (initiate 2 ng/kg/min and increase by 2 ng/kg/min every ≥15 minutes; CTEPH up to 45 ng/kg/min), documentation for reauthorization, 12‑month approvals (short‑term ≤30 days allowed if criteria not met or information is insufficient).

"Pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise capacity (FDA-approved indication)."